US20190313977A1 - Sensor Systems - Google Patents

Sensor Systems Download PDF

Info

Publication number
US20190313977A1
US20190313977A1 US16/449,169 US201916449169A US2019313977A1 US 20190313977 A1 US20190313977 A1 US 20190313977A1 US 201916449169 A US201916449169 A US 201916449169A US 2019313977 A1 US2019313977 A1 US 2019313977A1
Authority
US
United States
Prior art keywords
hydrogel
sensor
magnetic
sheath
sensors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/449,169
Inventor
Prashant Tathireddy
Carlos Mastrangelo
Florian Solzbacher
Nassir Marrouche
Jules Magda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation UURF
Original Assignee
University of Utah Research Foundation UURF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation UURF filed Critical University of Utah Research Foundation UURF
Priority to US16/449,169 priority Critical patent/US20190313977A1/en
Publication of US20190313977A1 publication Critical patent/US20190313977A1/en
Assigned to UNIVERSITY OF UTAH RESEARCH FOUNDATION reassignment UNIVERSITY OF UTAH RESEARCH FOUNDATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF UTAH
Assigned to UNIVERSITY OF UTAH reassignment UNIVERSITY OF UTAH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SOLZBACHER, FLORIAN, MAGDA, Jules, MASTRANGELO, CARLOS, TATHIREDDY, PRASHANT, MARROUCHE, NASSIR
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/68Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6846Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
    • A61B5/6847Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
    • A61B5/6852Catheters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/05Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14503Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14539Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring pH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14542Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring blood gases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14546Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/48Other medical applications
    • A61B5/4842Monitoring progression or stage of a disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/48Other medical applications
    • A61B5/4848Monitoring or testing the effects of treatment, e.g. of medication
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/68Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6846Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
    • A61B5/6847Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
    • A61B5/686Permanently implanted devices, e.g. pacemakers, other stimulators, biochips
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366Apparatus specially adapted for solid-phase testing
    • G01N33/54373Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
    • HELECTRICITY
    • H01ELECTRIC ELEMENTS
    • H01FMAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
    • H01F1/00Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
    • H01F1/0036Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
    • H01F1/0045Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/02Details of sensors specially adapted for in-vivo measurements
    • A61B2562/0223Magnetic field sensors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/02Details of sensors specially adapted for in-vivo measurements
    • A61B2562/0285Nanoscale sensors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/06Arrangements of multiple sensors of different types
    • A61B2562/063Arrangements of multiple sensors of different types in a linear array
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/06Arrangements of multiple sensors of different types
    • A61B2562/066Arrangements of multiple sensors of different types in a matrix array

Definitions

  • the present invention relates to sensor systems for detecting analytes and applications for such sensor systems.
  • the invention provides a sensor sheath for a catheter.
  • the sensor sheath includes a substrate having at least one sensor associated therewith; and an electronics unit in communication with the at least one sensor, wherein the substrate is configured to attach to a catheter.
  • the invention provides a sensor system.
  • the sensor system includes a substrate having a least one hydrogel sensor associated therewith; a magnetometer adjacent the at least one hydrogel sensor; and a plurality of magnetic particles associated with the at least one hydrogel sensor.
  • FIG. 1 shows an overview of a magnetic particle-hydrogel sensor system.
  • FIG. 2 shows a diagram of steps leading from a change in concentration of an analyte to a change in magnetic field in a magnetic particle-hydrogel sensor system.
  • FIG. 3 shows a sensor system associated with a catheter using a sheath which wraps around the catheter.
  • FIG. 4 shows an exploded view of an electronics system for use with a catheter-associated sensor system as shown in FIG. 3 .
  • FIG. 5 shows a distal end of a catheter (left) and a distal end of a sheath (right) to which one or more sensors may be attached and configured to wrap around a catheter.
  • FIG. 6 shows a distal end of a catheter sheath, in a flattened configuration, showing several sensors along with electrical traces.
  • FIG. 7 shows an embodiment of a sensor system which is mounted at the end of a probe, for example for use in a bioreactor.
  • FIG. 8 shows an embodiment of a sensor system which can be mounted under a subject's skin, with a magnetometer for measurement being located either under (top) or over (bottom) the subject's skin.
  • FIG. 9 shows another embodiment of a sensor system for use adjacent a subject's skin.
  • FIG. 10 shows a series of test samples of hydrogel having concentrations of 0.25% (left), 0.50% (center), or 1.0% (right) (w/w) of magnetic particles.
  • FIG. 11 shows an experimental setup for initial testing of magnetic field strength of samples such as those shown in FIG. 10 .
  • FIG. 12 is a graph of magnetic field strength vs. distance using the setup of FIG. 11 and the samples of FIG. 10 .
  • FIG. 13 shows changes in magnetic field strength as a function of distance
  • FIG. 14 shows changes in glucose concentration measured using a glucose-sensitive magnetic particle hydrogel.
  • FIG. 15 shows changes in ionic strength measured using an ionic strength-sensitive magnetic particle hydrogel.
  • FIG. 16 shows alignment of magnetic particles in a hydrogel in a Halbach array.
  • FIG. 17 shows alignment of magnetic particles in a hydrogel in a uniform array.
  • FIG. 18 shows a particle-containing layer on top of a hydrogel in which the particle-containing layer is perforated to permit the analyte to access the hydrogel.
  • the present invention includes sensor systems for various applications including medical and industrial uses.
  • the sensor system includes at least one hydrogel sensor, and in particular embodiments the at least one hydrogel sensor is a smart hydrogel sensor, as discussed further below.
  • the sensor system is associated with a substrate, where the substrate may be part of a specialized sensor system such as a sheath for attaching to a catheter or a probe for use in a bioreactor.
  • Hydrogel sensors take advantage of a change in measurable properties of hydrogels upon interaction with a particular analyte ( FIGS. 1-2 ).
  • the analyte may interact with a hydrogel itself or a binding moiety within the hydrogel to provoke a change in a measurable property of the hydrogel, and information regarding the analyte may be extracted by measuring the change in the measurable property.
  • the hydrogel-based sensor systems may include suitable mechanisms to detect the change in the measurable property.
  • Suitable hydrogels for use with this invention include any hydrogel that responds to the presence of an analyte with some change in at least one property of the hydrogel.
  • the hydrogel may respond to the presence of an analyte with a change in physical properties, electrical properties, optical properties, mechanical properties, chemical properties or a combination thereof.
  • the hydrogel may respond to the presence of an analyte with a change in size/volume, density, porosity, index of refraction, elasticity, viscosity, modulus or a combination thereof.
  • the hydrogel may respond to the presence of an analyte by swelling or shrinking relative to its initial volume.
  • the hydrogel may respond to the presence of an analyte by swelling to occupy at least about 1.001 times its initial volume, at least about 1.01, at least about 1.1, at least about 1.2, at least about 1.3, at least about 1.4, at least about 1.5, at least about 1.6, at least about 1.7, at least about 1.8, at least about 1.9, at least about 2.0, at least about 2.5, at least about 3.0, at least about 3.5, at least about 4.0, at least about 4.5, at least about 5.0, at least about 6.0, at least about 7.0, at least about 8.0, at least about 9.0, at least about 10.0, at least about 11.0, at least about 12.0, at least about 13.0, at least about 14.0, at least about 15.0, at least about 20.0, or at least about 25.0 times its initial volume.
  • the hydrogel may response to the presence of an analyte by swelling to occupy at most about 100 times its initial volume, at most about 90, at most about 80, at most about 75, at most about 70, at most about 65, at most about 60, at most about 55, at most about 50.0, at most about 45.0, at most about 40.0, at most about 35.0, at most about 30.0, at most about 29.0, at most about 28.0, at most about 27.0, at most about 26.0, at most about 25.0, at most about 24.0, at most about 23.0, at most about 22.0, at most about 21.0, at most about 20.0, at most about 19.0, at most about 18.0, at most about 17.0, at most about 16.0, at most about 15.0, at most about 14.0, at most about 13.0, at most about 12.0, at most about 11.0, at most about 10.0, at most about 9.0, at most about 8.0, at most about 7.0, at most about 6.0, or at most about 5.0 times it initial volume
  • hydrogel responds to the presence of an analyte by swelling to occupy volumes ranging from about 1.001 to about 100 times its initial volume, including, but not limited to, volumes ranging from about 1.01 to about 50 times its initial volume, or volumes ranging from about 1.1 to about 25.0 times its initial volume.
  • the hydrogel may comprise a smart hydrogel.
  • smart hydrogel refers to a hydrogel's ability to selectively bind one or more particular analyte species at the selective exclusion of one or more other species.
  • the hydrogel may comprise a material selected from the group consisting of synthetic materials, biological materials, biohybrid materials, and combinations thereof.
  • the hydrogel may comprise a material selected from the group consisting of poly(acrylic acid) and derivatives thereof, poly(2-glucosyloxyethyl methacrylate) (poly(GEMA)) and derivatives thereof, poly(hydroxyethyl methacrylate) (PHEMA) and derivatives thereof, poly(ethylene glycol) (PEG) and derivatives thereof, poly(vinyl alcohol) (PVA) and derivatives thereof, polyacrylamide (PAAm) and derivatives thereof, poly(methacrylic) acid and derivatives thereof, poly(diethylaminoethyl methacrylate) and derivatives thereof, poly(dimethylaminoethyl methacrylate) and derivatives thereof, poly(N-isopropylacrylamide) (PNIPAAm) and derivatives thereof, Polyelectrolyte multilayers (PEM), Polyelectrolyte multi
  • the hydrogel may comprise a material selected from the group consisting of proteins, polysaccharides, DNA, and combinations thereof.
  • the hydrogel may comprise a material selected from the group consisting of collagen, hyaluronic acid (HA), fibrin, alginate, agarose, chitosan, and combinations thereof.
  • the hydrogel may comprise one or more specific binding sites.
  • the specific binding sites may be responsible for imparting the “smart” nature of a hydrogel.
  • the specific binding site may comprise reversible or non-reversible binding sites.
  • suitable hydrogels for use with this invention include, but are not limited to, those disclosed in U.S. Pat. Nos. 5,415,864, 5,447,727, 6,268,161, 6,333,109, 6,475,750, 6,514,689, 6,753,191, 6,835,553, 6,848,384, 7,150,975, 7,179,487, 7,556,934, 7,625,951, 7,988,685, 8,221,773, 8,283,384, and 8,324,184, and U.S. Patent Application Pub. Nos.
  • the sensor system includes one or more sensors coupled to a substrate that is associated with a catheter ( FIGS. 3-6 ).
  • the hydrogels may be situated on a substrate that is part of a sheath which is associated with an outer surface of the catheter.
  • the hydrogels may be “smart” hydrogels which are chemically designed to reversibly and selectively bind to analytes dissolved in blood serum, such as fibrinogen and various clotting factors including, but not limited to, thrombin. Binding of an analyte to the appropriate hydrogel may be detected in a number of ways, generally involving detection of a change in size or pressure resulting from the binding of the analyte to the hydrogel, including piezoresistive pressure transducers, magnetometers (discussed below), or other means of converting the hydrogel size or shape change into an electrical signal. Other hydrogel changes that may occur include changes in impedance or fluorescence. By continuously monitoring these electrical signals, the serum concentration of analytes such as fibrinogen or various clotting factors such as thrombin may be accurately and rapidly determined as a function of time.
  • a sensor system associated with a catheter relates to tests of blood coagulation that are used to monitor the anticoagulant effect of heparin or other anticoagulants infused into patients during heart surgery or during stays in critical care facilities.
  • a cardiovascular event such as a myocardial infarction or during heart surgery
  • the anticoagulant infusion rate must be continuously adjusted using the results of coagulation tests performed on the blood such as the Activated Clotting Time (ACT).
  • ACT Activated Clotting Time
  • ACT test whole blood is intermittently removed from the patient, placed in a tube outside the body, and the time to clot is measured after addition to the blood of a clotting activator such as diatomaceous earth.
  • a clotting activator such as diatomaceous earth.
  • the current technology for the ACT test suffers from limitations such as slow response time, intermittent measurements, and the necessity of removing the blood sample for analysis outside of the patient's body.
  • thrombin generation test Another blood coagulation test that is more diagnostic than the ACT test is the endogenous thrombin generation test.
  • Thrombin is the primary enzyme found in blood coagulation, and the endogenous thrombin generation test measures the conversion kinetics of a synthetic thrombin substrate.
  • the current technology for the endogenous thrombin generation test also suffers from limitations such as slow response time, intermittent measurements, and the necessity of removing a blood sample from the patient's body. Methods have been proposed for the continuous measurement of the thrombin concentration in blood, using thrombin recognition elements such fibrinogen, aptamers for thrombin, and molecularly-imprinted aptamers for thrombin.
  • prior art does not teach a method for simultaneous and continuous measurement in vivo of the concentration of multiple clotting factors. Methods have also been proposed for the measurement of the soluble fibrinogen concentration in aqueous solutions. However, prior art does not teach a method for continuous real-time measurement in vivo of the fibrinogen concentration using stimuli-responsive hydrogels as a replacement for the ACT test.
  • a sensor system provides a sensor array associated with an indwelling catheter for continuously measuring the concentration of fibrinogen, thrombin, and/or other various clotting factors within blood.
  • the sensor array may contain several different types of stimuli-responsive (i.e. “smart”) hydrogels for selective and reversible binding of the analytes of interest.
  • a stimuli-responsive smart hydrogel is a cross-linked polymer network that reversibly changes its properties in response to the change in a given environmental signal, including a change in the concentration of an analyte such as thrombin.
  • a stimuli-responsive hydrogel can be fabricated to be responsive to a given analyte.
  • molecular imprinting polymerization of a “functional” monomer is carried out in the presence of a porogenic solvent and the target analyte, the latter which is called the ‘template’. After crosslinking/polymerization, the template is extracted, leaving behind cavities that contain a stereochemical arrangement of functional groups corresponding to the structure of the template. Hence the cavities will re-bind the analyte with high selectivity and sensitivity.
  • a functional monomer needs be chosen that forms strong yet reversible physical bonds with the template molecule.
  • Reversibility of analyte binding can be obtained by varying the identity and mole ratio of the functional monomers used to synthesize the imprinted hydrogel.
  • imprinted hydrogels can be obtained which reversibly bind proteins such as lysozyme, fibrinogen, and tumor-specific glycoproteins.
  • suitable functional monomers can include methacrylic acid and 3-acyrliamido phenyl boronic acid. The latter contains the boronic acid moiety which can reversibly bind to the glycosylated regions of thrombin.
  • Binding of the correct analyte(s) to the appropriate hydrogel will induce a change in a property of the hydrogel such as swelling degree, impedance, fluorescence, and/or magnetic field, each of which may be transduced into an electrical signal. These electrical signals can then be used to rapidly and continuously monitor the blood concentration of the analytes of interest.
  • blood in order to determine the ACT time blood will flow in or adjacent the catheter past a fibrinogen-responsive hydrogel after flowing through a porous bed of clotting activator such as diatomaceous earth. The clotting activator will initiate clotting and the subsequent incorporation of soluble fibrinogen into fibrin-based blood clots.
  • time-dependent clot formation and the ACT can be determined from the measured decrease in fibrinogen concentration.
  • the increase in thrombin concentration can be measured from the signal obtained from the thrombin-responsive hydrogel and correlated to the endogenous thrombin potential. Because binding of the analytes to the hydrogels will be rapid and reversible, it will be possible to measure the value of the ACT and the endogenous thrombin potential continuously in vivo, which are distinct advantages relative to known systems.
  • a catheter-associated sensor system may include a sheath with one or more sensors attached thereto where the sheath can be attached to a catheter, for example by attaching to a side of, or wrapping around, the catheter ( FIGS. 3-6 ).
  • the sheath is fabricated using flex circuits (e.g. made of materials such as Parylene, Silicones, Polyurethanes, or Polyimides) so that the sheath can be wrapped around another structure such as a catheter.
  • a sheath designed for catheter mounting may be elongated so that it can be wrapped around the shaft of the catheter.
  • the sheath may wrap around the entire length of the catheter or just at the distal end ( FIGS. 3, 5 ).
  • the sheath may be formed into a curled shape (for example during a curing process, e.g. using heat; see FIGS. 3, 5 ) or the sheath may be rolled and joined along the edge to retain the rolled shape, and/or the sheath may be attached to the catheter, e.g. using adhesive, to help maintain the curled shape.
  • the sheath may have one or more sensors associated therewith, for example located at the distal end or disposed along its length ( FIGS. 3, 5, 6 ).
  • the sensors may include hydrogel sensors, and in one particular embodiment the sensors may be magnetic hydrogel sensors.
  • the sheath includes a narrow body with a wide portion at a distal end.
  • One or more sensors are attached to the sheath at the wide portion, which wraps around a distal end of the catheter ( FIGS. 3, 5, 6 ).
  • a plurality of electrical connections run from each sensor along the narrow body of the sheath to the proximal end, where the electrical connections connect with an electronics unit, which collects data from the sensors.
  • the electronics unit may also include a power supply (e.g. one or more batteries) and a telemetry system including an antenna for wireless communications (e.g. for receiving commands and transmitting data) ( FIG. 4 ).
  • Wireless communications may be conducted using any number of suitable protocols such as Bluetooth or ZigBee.
  • the electronics unit may communicate with other computers or smartphones that are local or remote from the sheath using wireless communications or in a wired configuration. Data transfer may be initiated in several ways, including by activation of a touch-sensitive switch on the electronics unit.
  • the electronics unit may be housed in a small package that can be mounted at an end of the catheter, for example distal from the location of the sensors. In some embodiments the narrow body of the sheath may extend through a coupling of the catheter and connect to the electronics unit inside the coupling ( FIG. 4 ).
  • the sheath may be made of one or more flexible and/or biocompatible materials (e.g. Parylene, Silicones, PU, PI) and has embedded therein electrical traces and interconnects from the sensor array to a circular processor unit.
  • the processor unit may be dimensioned such as to fit exactly on the top part of the catheter structure, extending the length by less than 5 mm.
  • sensors can be used with the sheath, although in one particular embodiment the sensors include smart hydrogels with magnetic particles associated therewith in which a magnetometer is used to detect changes in the hydrogel due to interaction with the analyte (see below).
  • the sensors that may be used with the sheath include amperometric (current), potentiometric (voltage), optical (e.g. fluorescence), mechanical (e.g. pressure, volume), magnetic, and inductive (RF frequency shift) sensors.
  • sensing mechanisms may include various enzymatic and non-enzymatic mechanisms including those employing antibodies and other protein-based sensors.
  • the disclosed catheter sheath sensor system allows intraprocedural, real-time monitoring of changes in electrolytes, blood coagulation status, and injury markers (enzyme etc.) and will save a significant amount of blood draws, additional testing and ensure a higher level of safety by detecting changes in critical blood values as they happen in real-time.
  • an array having one or more sensors is located at the end of a probe to be inserted into the bioreactor ( FIG. 7 ).
  • the probe may have two or more separate portions including a disposable sleeve containing one or more sensors (e.g. hydrogel sensors) and a magnetic detector insert which is inserted into the sleeve.
  • the sleeve interacts with the contents of the bioreactor while the magnetic detector insert is shielded from the contents and therefore can be reused.
  • magnetic hydrogel sensors such as those disclosed herein, because the magnetic detectors can monitor changes in the magnetic particles associated with the hydrogel sensors without making direct contact.
  • the sleeve in various embodiments may include a porous end portion (e.g. a hemispherical mesh cover as shown) which permits passage of analytes so that the analytes can interact with the sensors while protecting the sensors.
  • the electronics for controlling the sensors may be included in the insert portion of the probe adjacent to the magnetic detectors or may be at a remote location.
  • the sensor system includes magnetic hydrogel sensors.
  • Magnetic hydrogel sensors use hydrogels, including smart hydrogels, as described above, in which the hydrogel changes shape due to its interaction with an analyte, and detection of the change in the measurable property is detected using magnetic particles, including nanoparticles, associated with the hydrogel.
  • the volumetric response of stimuli-responsive hydrogels can be monitored by measuring the change in magnetic field intensity (MFI) by the embedded magnetic nanoparticles.
  • MFI magnetic field intensity
  • Nanoparticles have previously been embedded in hydrogels as part of controlled drug-delivery applications, although the techniques disclosed herein are versatile and can be used in a wide range of applications.
  • the specific chemistry of the synthesized hydrogels causes them to respond to a unique stimulus (e.g. interaction with an analyte) by swelling or deswelling 00% their original volume in proportion to the concentration or intensity of the stimulus.
  • the magnetic particles or nanoparticles may be arranged in a particular alignment in or adjacent to the hydrogel.
  • the sensor system includes a smart hydrogel having magnetic nanoparticles embedded therein, where the magnetic fields of the nanoparticles are vertically aligned.
  • the vertically aligned magnetic nanoparticles embedded in the smart hydrogels will transduce the hydrogel actuation as a change in magnetic field intensity in and around the hydrogel, which is detected by a magnetometer adjacent to the hydrogel ( FIGS. 1, 2 ).
  • This approach provides several advantages relative to other techniques for monitoring hydrogels such as monitoring pressure changes caused by swelling of the hydrogel, chemical sensing techniques (e.g. electrochemical methods), and optical sensing techniques.
  • the hydrogels can be adapted in a number of ways to respond to concentrations of almost any analyte, expanding the potential impact of the proposed technique enormously.
  • One advantage of the disclosed magnetic nanoparticle hydrogel sensor system is its ability to respond to multiple analytes using different hydrogels within the same sensor platform and its adaptability to a wide variety of sensing applications such as in bioreactor composition sensing, point-of-care medical treatment, or as fully-implantable, chronic (continuous) sensors of physiological biomarkers to monitor diseases or treatment states.
  • passive ‘magnetic-hydrogel’ composites may be implanted in a subject's subcutaneous region and active components may be placed on the skin surface for long-term continuous monitoring of biomarkers ( FIG. 8 ).
  • an array of sensors may be implanted under a subject's skin with a wired connection to an electronics unit outside the surface of the subject's skin ( FIG. 8 , top).
  • an array of magnetic particle-hydrogel sensors is implanted under the subject's skin and a magnetometer and electronics unit is placed over the hydrogel sensors to detect changes in the magnetic fields induced by analyte-dependent changes in the hydrogels ( FIG. 8 , bottom).
  • a pair of magnetic particle-hydrogel sensors may be implanted near one another, with one being sensitive to an analyte (e.g. glucose) and the other being analyte-insensitive ( FIG. 9 ).
  • Magnetometer readings are then collected from both sensors and a differential signal is determined based on the pairs of readings, canceling out changes in signal due to factors other than changes in analyte level, such as the subject's hydration level and body temperature, among other factors.
  • Sensors may be located in a subject's skin in one or more locations throughout the subject's body including in the arms, legs, torso, or head (including, for example, the earlobe).
  • FIG. 13 shows the sensitivity of an off-the-shelf magnetometer. Measured changes in the magnetic field are due the movement of a magnetic strip by 5 micrometer increments 2 mm above the magnetometer. The magnetic strip was moved using an automatic (computer controlled) linear actuator 20 times from 0-200 micrometers and the data shows excellent repeatability. This experiment was conducted to demonstrate the ability of magnetically measuring fine physical movements relatively far away (three orders of magnitude) from a low-cost magnetometer.
  • FIG. 13 shows the sensitivity of an off-the-shelf magnetometer. Measured changes in the magnetic field are due the movement of a magnetic strip by 5 micrometer increments 2 mm above the magnetometer. The magnetic strip was moved using an automatic (computer controlled) linear actuator 20 times from 0-200 micrometers and the data shows excellent repeatability. This experiment was conducted to demonstrate the ability of magnetically measuring fine physical movements relatively far away (three orders of magnitude) from a low-cost magnetometer.
  • FIG. 13 shows the sensitivity of an off-the-shelf magnetometer. Measured changes in the
  • the hydrogel is synthesized to be glucose responsive and a prefabricated magnetic film was placed over the hydrogel to form the magnetic hydrogel.
  • the hydrogel was attached to the inside wall a glass-beaker while the magnetometer was aligned to the hydrogel on the outside of the beaker.
  • glucose concentration was changed from 0 mM to 5 mM and the resulting change in the magnetic field was measured using the magnetometer.
  • the solution in the beaker was mildly stirred throughout the experiment. The data artifact seen after the first cycle in FIG. 14 is caused during the act of changing solutions in the beaker.
  • the setup used in experiment that resulted in FIG. 15 is similar to that described above for FIG. 14 .
  • the hydrogel used was one sensitive to ionic strength. Ionic strength was changed using an automatic flow control system from 1 ⁇ to 2 ⁇ PBS in the beaker and the change in magnetic field was measured using the magnetometer. The drift in the data is caused due to the conditioning of the hydrogel.
  • the disclosed sensors may be adapted for use in a variety of fields.
  • sensors may be adapted for diagnosing and monitoring symptoms related to addiction, depression, Parkinson's disease, stroke, and blood pressure.
  • sensors may be adapted for detection of smoking, monitoring intake of various medications and other drugs, and monitoring changes in acid levels in the esophagus and stomach.
  • sensors may be adapted for monitoring of inhalers as well as diagnosis, monitoring, and management of symptoms related to conditions of the lungs such as asthma and chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • sensors may be adapted for use related to interventional procedures such as monitoring of pH, electrolytes, glucose, troponin, C-reactive protein, troponin, cholesterol components, and guidance and monitoring use of anticoagulants such as monitoring of factors Xa and thrombin.
  • sensors may be adapted for use with devices such as ICD leads (e.g. for sensing of heart failure and heart attacks), PM leads (e.g. for monitoring of heart failure and heart attacks), and for monitoring clot formation including thrombin generation (thrombin-antithrombin [TAT] complex), endothelial dysfunction (asymmetric dimethylarginine [ADMA]), and platelet-derived inflammation (soluble CD40 ligand [sCD40L]).
  • ICD leads e.g. for sensing of heart failure and heart attacks
  • PM leads e.g. for monitoring of heart failure and heart attacks
  • clot formation including thrombin generation (thrombin-antithrombin [TAT] complex), endothelial dysfunction (asymmetric dimethylargin
  • sensors may be adapted for monitoring and/or diagnosing liver enzymes, hepatitis C, fat liver, and liver transplants; in addition, pancreatic activity can be evaluated through monitoring of blood glucose levels in order to assess an individual's or population's diabetes risk level.
  • sensors may be adapted for measuring creatinine levels, monitoring kidney transplants, and monitoring the physiology of dialysis patients.
  • sensors may be adapted for monitoring iron and hemoglobin levels as well as diagnosing and monitoring treatment of blood cancers (e.g. detecting particular markers).
  • sensors may be adapted for monitoring the prostate including PSA levels.
  • sensors may be adapted for use before, during, and after surgery to monitor a subject's levels of pH, electrolytes, blood anticoagulation factors, hemoglobin, and lactate levels.
  • a particular advantage of the proposed approach is its ability to respond to multiple analytes using different hydrogels within the same sensor platform and its adaptability to a wide variety of sensing applications such as in bioreactor composition sensing, point-of-care medical treatment, or as fully implantable, chronic sensors of physiological biomarkers to monitor diseases or treatment states; and
  • the disclosed sensors are expected to have fewer problems due to a subject's body reacting to foreign objects associated with the sensor because the implanted portion can be as little as the passive hydrogel portion, while the remaining detection components (e.g. the magnetometer and related electronics) can be placed on the surface of the subject's body/skin.
  • the remaining detection components e.g. the magnetometer and related electronics
  • the sensing MFI range of the proposed sensor in some embodiments may range from about 300 ⁇ T to about 4000 ⁇ T. While this range is much higher than the earth's magnetic field range (25-65 ⁇ T), it is lower than that seen in magnetic resonance imaging (MRI). Sensor readings may be influenced by strong external magnetic fields, although one way to overcome this limitation may be to have an auxiliary reference magnetometer at a distance from the sensor, for example in a hand-held monitoring device, so that differential magnetic readings can be taken.
  • FIGS. 16 and 17 show alignment of magnetic particles in or adjacent to a hydrogel.
  • FIGS. 16 and 17 each show a hydrogel mounted on a substrate with a layer containing magnetic particles on top of the hydrogel.
  • the hydrogel may be continuously attached to the substrate during use, or the substrate may only be present during formation of the hydrogel and removed from the hydrogel prior to use.
  • a larger portion of the hydrogel (with or without a separate top layer) may be made and then divided into smaller sections for use.
  • a magnetometer is placed near the hydrogel, for example under the substrate, when present, or near the hydrogel, to detect magnetic fields from the particles associated with the hydrogel.
  • the hydrogel itself may contain the particles.
  • the particle-containing layer when present, may be solid or it may be porous or contain perforations to permit access by the analytes to the hydrogel ( FIG. 18 ).
  • the particle-containing layer may be made of a hydrogel (the same or different from the underlying hydrogel), another polymer, or silicone, among various possible materials.
  • a hydrogel and/or top layer may be formed according to the following procedures:
  • this layer may then be placed over an analyte-sensitive hydrogel.
  • the depth of the plane along which the particles are aligned may be altered by controlling the magnitude of the externally-applied magnetic fields during the curing process.
  • the magnetic particles in FIG. 16 are arranged in a Halbach array ( FIG. 16 , inset).
  • the particular arrangement of particles e.g. with adjacent vertically-aligned and horizontally-aligned particles having their magnetic fields in opposite directions
  • FIG. 17 shows another arrangement in which the particles are uniformly aligned, for example horizontally, as shown ( FIG. 17 , inset), or vertically.
  • the magnetic fields extend relatively equally in both directions away from the plane of the hydrogel or particle layer.
  • the operating distance at which the magnetic fields are detectable range from tens of micrometers to several millimeters from the particles.
  • the Halbach array or uniform magnetic field may be generated in the layer or hydrogel by subjecting the layer or hydrogel to a suitable magnetic field during curing.
  • the Halbach array particle arrangement may be realized in one of several possible ways: (1) one way to generate this array is to dispense ferromagnetic particles in a polymer homogeneously and form a magnetic composite sheet, as discussed above, and then magnetize the sheet using a magnetizer with a pre-configured pattern.
  • Polymers that can be used for example but not limited to, are silicones, polyurethanes, polyethylenes, hydrogels, and other polymers; (2) another way is to select a prefabricated, commercially-available Halbach array sheet material and use it to ‘mirror’ its magnetic arrangement into the hydrogel.
  • Possible magnetic nanoparticle materials include permanent magnetic particles such as ferro- or ferri-magnetic particles, rare-earth alloys (samarium-cobalt, neodymium-iron-boron), ceramic ferrites (barium or strontium ferrite), and other magnetic materials.
  • the magnetic particle/nanoparticle sizes may range from 20 nm to tens of micrometers, with a typical size being about 1 micrometer.
  • hydrogel-based sensor systems may be used to determine the presence and levels of the various analytes.

Abstract

A sensor sheath for a catheter. The sensor sheath includes a substrate having at least one sensor associated therewith and an electronics unit in communication with the at least one sensor, wherein the substrate is configured to attach to a catheter.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application claims priority to U.S. patent application Ser. No. 14/774,070 filed Sep. 9, 2015 and tilted “SENSOR SYSTEMS,” which is a national stage entry of PCT Application No. PCT/US14/23352, filed Mar. 11, 2014 and titled “SENSOR SYSTEMS,” which claims priority to U.S. Provisional Patent Application No. 61/927,683 filed Jan. 15, 2014 and titled “SENSOR SYSTEMS,” and to U.S. Provisional Patent Application No. 61/851,603 filed Mar. 11, 2013, titled “MAGNETIC SENSING OF SMART-HYDROGEL RESPONSE.” Each of the foregoing is incorporated herein by reference in its entirety.
  • BACKGROUND
  • The present invention relates to sensor systems for detecting analytes and applications for such sensor systems.
  • There is a continuing need for improved sensor systems for medical and industrial purposes.
  • SUMMARY
  • In one embodiment, the invention provides a sensor sheath for a catheter. The sensor sheath includes a substrate having at least one sensor associated therewith; and an electronics unit in communication with the at least one sensor, wherein the substrate is configured to attach to a catheter.
  • In another embodiment the invention provides a sensor system. The sensor system includes a substrate having a least one hydrogel sensor associated therewith; a magnetometer adjacent the at least one hydrogel sensor; and a plurality of magnetic particles associated with the at least one hydrogel sensor.
  • Other aspects of the invention will become apparent by consideration of the detailed description and accompanying drawings.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided upon request and payment of the necessary fee.
  • FIG. 1 shows an overview of a magnetic particle-hydrogel sensor system.
  • FIG. 2 shows a diagram of steps leading from a change in concentration of an analyte to a change in magnetic field in a magnetic particle-hydrogel sensor system.
  • FIG. 3 shows a sensor system associated with a catheter using a sheath which wraps around the catheter.
  • FIG. 4 shows an exploded view of an electronics system for use with a catheter-associated sensor system as shown in FIG. 3.
  • FIG. 5 shows a distal end of a catheter (left) and a distal end of a sheath (right) to which one or more sensors may be attached and configured to wrap around a catheter.
  • FIG. 6 shows a distal end of a catheter sheath, in a flattened configuration, showing several sensors along with electrical traces.
  • FIG. 7 shows an embodiment of a sensor system which is mounted at the end of a probe, for example for use in a bioreactor.
  • FIG. 8 shows an embodiment of a sensor system which can be mounted under a subject's skin, with a magnetometer for measurement being located either under (top) or over (bottom) the subject's skin.
  • FIG. 9 shows another embodiment of a sensor system for use adjacent a subject's skin.
  • FIG. 10 shows a series of test samples of hydrogel having concentrations of 0.25% (left), 0.50% (center), or 1.0% (right) (w/w) of magnetic particles.
  • FIG. 11 shows an experimental setup for initial testing of magnetic field strength of samples such as those shown in FIG. 10.
  • FIG. 12 is a graph of magnetic field strength vs. distance using the setup of FIG. 11 and the samples of FIG. 10.
  • FIG. 13 shows changes in magnetic field strength as a function of distance
  • FIG. 14 shows changes in glucose concentration measured using a glucose-sensitive magnetic particle hydrogel.
  • FIG. 15 shows changes in ionic strength measured using an ionic strength-sensitive magnetic particle hydrogel.
  • FIG. 16 shows alignment of magnetic particles in a hydrogel in a Halbach array.
  • FIG. 17 shows alignment of magnetic particles in a hydrogel in a uniform array.
  • FIG. 18 shows a particle-containing layer on top of a hydrogel in which the particle-containing layer is perforated to permit the analyte to access the hydrogel.
  • DETAILED DESCRIPTION
  • Before any embodiments of the invention are explained in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the following drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways.
  • In various embodiments, the present invention includes sensor systems for various applications including medical and industrial uses. In some embodiments, the sensor system includes at least one hydrogel sensor, and in particular embodiments the at least one hydrogel sensor is a smart hydrogel sensor, as discussed further below. In certain embodiments the sensor system is associated with a substrate, where the substrate may be part of a specialized sensor system such as a sheath for attaching to a catheter or a probe for use in a bioreactor.
  • Hydrogel Sensors
  • Hydrogel sensors take advantage of a change in measurable properties of hydrogels upon interaction with a particular analyte (FIGS. 1-2). Generally, the analyte may interact with a hydrogel itself or a binding moiety within the hydrogel to provoke a change in a measurable property of the hydrogel, and information regarding the analyte may be extracted by measuring the change in the measurable property. Accordingly, the hydrogel-based sensor systems may include suitable mechanisms to detect the change in the measurable property.
  • Suitable hydrogels for use with this invention include any hydrogel that responds to the presence of an analyte with some change in at least one property of the hydrogel. In certain embodiments, the hydrogel may respond to the presence of an analyte with a change in physical properties, electrical properties, optical properties, mechanical properties, chemical properties or a combination thereof. In certain embodiments, the hydrogel may respond to the presence of an analyte with a change in size/volume, density, porosity, index of refraction, elasticity, viscosity, modulus or a combination thereof. In certain embodiments, the hydrogel may respond to the presence of an analyte by swelling or shrinking relative to its initial volume.
  • In certain embodiments, the hydrogel may respond to the presence of an analyte by swelling to occupy at least about 1.001 times its initial volume, at least about 1.01, at least about 1.1, at least about 1.2, at least about 1.3, at least about 1.4, at least about 1.5, at least about 1.6, at least about 1.7, at least about 1.8, at least about 1.9, at least about 2.0, at least about 2.5, at least about 3.0, at least about 3.5, at least about 4.0, at least about 4.5, at least about 5.0, at least about 6.0, at least about 7.0, at least about 8.0, at least about 9.0, at least about 10.0, at least about 11.0, at least about 12.0, at least about 13.0, at least about 14.0, at least about 15.0, at least about 20.0, or at least about 25.0 times its initial volume. In certain embodiments, the hydrogel may response to the presence of an analyte by swelling to occupy at most about 100 times its initial volume, at most about 90, at most about 80, at most about 75, at most about 70, at most about 65, at most about 60, at most about 55, at most about 50.0, at most about 45.0, at most about 40.0, at most about 35.0, at most about 30.0, at most about 29.0, at most about 28.0, at most about 27.0, at most about 26.0, at most about 25.0, at most about 24.0, at most about 23.0, at most about 22.0, at most about 21.0, at most about 20.0, at most about 19.0, at most about 18.0, at most about 17.0, at most about 16.0, at most about 15.0, at most about 14.0, at most about 13.0, at most about 12.0, at most about 11.0, at most about 10.0, at most about 9.0, at most about 8.0, at most about 7.0, at most about 6.0, or at most about 5.0 times it initial volume. This includes embodiments where the hydrogel responds to the presence of an analyte by swelling to occupy volumes ranging from about 1.001 to about 100 times its initial volume, including, but not limited to, volumes ranging from about 1.01 to about 50 times its initial volume, or volumes ranging from about 1.1 to about 25.0 times its initial volume.
  • In certain embodiments, the hydrogel may comprise a smart hydrogel. As used herein, the term “smart” refers to a hydrogel's ability to selectively bind one or more particular analyte species at the selective exclusion of one or more other species.
  • In certain embodiments, the hydrogel may comprise a material selected from the group consisting of synthetic materials, biological materials, biohybrid materials, and combinations thereof. In certain embodiments, the hydrogel may comprise a material selected from the group consisting of poly(acrylic acid) and derivatives thereof, poly(2-glucosyloxyethyl methacrylate) (poly(GEMA)) and derivatives thereof, poly(hydroxyethyl methacrylate) (PHEMA) and derivatives thereof, poly(ethylene glycol) (PEG) and derivatives thereof, poly(vinyl alcohol) (PVA) and derivatives thereof, polyacrylamide (PAAm) and derivatives thereof, poly(methacrylic) acid and derivatives thereof, poly(diethylaminoethyl methacrylate) and derivatives thereof, poly(dimethylaminoethyl methacrylate) and derivatives thereof, poly(N-isopropylacrylamide) (PNIPAAm) and derivatives thereof, Polyelectrolyte multilayers (PEM), Poly(2-oxazoline)s and derivatives thereof, and combinations thereof. In certain embodiments, the hydrogel may comprise a material selected from the group consisting of proteins, polysaccharides, DNA, and combinations thereof. In certain embodiments, the hydrogel may comprise a material selected from the group consisting of collagen, hyaluronic acid (HA), fibrin, alginate, agarose, chitosan, and combinations thereof.
  • In certain embodiments, the hydrogel may comprise one or more specific binding sites. The specific binding sites may be responsible for imparting the “smart” nature of a hydrogel. In certain embodiments, the specific binding site may comprise reversible or non-reversible binding sites.
  • Examples of suitable hydrogels for use with this invention include, but are not limited to, those disclosed in U.S. Pat. Nos. 5,415,864, 5,447,727, 6,268,161, 6,333,109, 6,475,750, 6,514,689, 6,753,191, 6,835,553, 6,848,384, 7,150,975, 7,179,487, 7,556,934, 7,625,951, 7,988,685, 8,221,773, 8,283,384, and 8,324,184, and U.S. Patent Application Pub. Nos. 2005/0169882, 2006/0239986, 2008/0206894, 2008/0044472, 2008/0275171, 2008/0311670, 2009/0170209, 2009/0215923, 2010/0285094, 2011/0044932, 2011/0280914, 2012/0170050, 2012/0029430, 2012/0234465, 2013/0129797, 2013/0143821, and 2013/0172985, and 2013/0267455, each of which is incorporated herein by reference in its entirety.
  • Catheter Sensors
  • In some embodiments the sensor system includes one or more sensors coupled to a substrate that is associated with a catheter (FIGS. 3-6). In one such embodiment, the hydrogels may be situated on a substrate that is part of a sheath which is associated with an outer surface of the catheter.
  • As discussed above, the hydrogels may be “smart” hydrogels which are chemically designed to reversibly and selectively bind to analytes dissolved in blood serum, such as fibrinogen and various clotting factors including, but not limited to, thrombin. Binding of an analyte to the appropriate hydrogel may be detected in a number of ways, generally involving detection of a change in size or pressure resulting from the binding of the analyte to the hydrogel, including piezoresistive pressure transducers, magnetometers (discussed below), or other means of converting the hydrogel size or shape change into an electrical signal. Other hydrogel changes that may occur include changes in impedance or fluorescence. By continuously monitoring these electrical signals, the serum concentration of analytes such as fibrinogen or various clotting factors such as thrombin may be accurately and rapidly determined as a function of time.
  • One particular use of a sensor system associated with a catheter relates to tests of blood coagulation that are used to monitor the anticoagulant effect of heparin or other anticoagulants infused into patients during heart surgery or during stays in critical care facilities. After a cardiovascular event such as a myocardial infarction or during heart surgery, it is common practice to infuse into a patient an anticoagulant such a heparin in order to reduce the risk of blood clots. For a given patient, the anticoagulant infusion rate must be continuously adjusted using the results of coagulation tests performed on the blood such as the Activated Clotting Time (ACT). In the ACT test, whole blood is intermittently removed from the patient, placed in a tube outside the body, and the time to clot is measured after addition to the blood of a clotting activator such as diatomaceous earth. The current technology for the ACT test suffers from limitations such as slow response time, intermittent measurements, and the necessity of removing the blood sample for analysis outside of the patient's body.
  • Another blood coagulation test that is more diagnostic than the ACT test is the endogenous thrombin generation test. Thrombin is the primary enzyme found in blood coagulation, and the endogenous thrombin generation test measures the conversion kinetics of a synthetic thrombin substrate. The current technology for the endogenous thrombin generation test also suffers from limitations such as slow response time, intermittent measurements, and the necessity of removing a blood sample from the patient's body. Methods have been proposed for the continuous measurement of the thrombin concentration in blood, using thrombin recognition elements such fibrinogen, aptamers for thrombin, and molecularly-imprinted aptamers for thrombin. However, the prior art does not teach a method for simultaneous and continuous measurement in vivo of the concentration of multiple clotting factors. Methods have also been proposed for the measurement of the soluble fibrinogen concentration in aqueous solutions. However, prior art does not teach a method for continuous real-time measurement in vivo of the fibrinogen concentration using stimuli-responsive hydrogels as a replacement for the ACT test.
  • The present embodiment of a sensor system provides a sensor array associated with an indwelling catheter for continuously measuring the concentration of fibrinogen, thrombin, and/or other various clotting factors within blood. The sensor array may contain several different types of stimuli-responsive (i.e. “smart”) hydrogels for selective and reversible binding of the analytes of interest. In various embodiments, a stimuli-responsive smart hydrogel is a cross-linked polymer network that reversibly changes its properties in response to the change in a given environmental signal, including a change in the concentration of an analyte such as thrombin.
  • One way that a stimuli-responsive hydrogel can be fabricated to be responsive to a given analyte is using the process of molecular imprinting. In molecular imprinting, polymerization of a “functional” monomer is carried out in the presence of a porogenic solvent and the target analyte, the latter which is called the ‘template’. After crosslinking/polymerization, the template is extracted, leaving behind cavities that contain a stereochemical arrangement of functional groups corresponding to the structure of the template. Hence the cavities will re-bind the analyte with high selectivity and sensitivity. For best results, a functional monomer needs be chosen that forms strong yet reversible physical bonds with the template molecule. Reversibility of analyte binding can be obtained by varying the identity and mole ratio of the functional monomers used to synthesize the imprinted hydrogel. For example, imprinted hydrogels can be obtained which reversibly bind proteins such as lysozyme, fibrinogen, and tumor-specific glycoproteins. For reversible binding of thrombin, suitable functional monomers can include methacrylic acid and 3-acyrliamido phenyl boronic acid. The latter contains the boronic acid moiety which can reversibly bind to the glycosylated regions of thrombin.
  • Binding of the correct analyte(s) to the appropriate hydrogel will induce a change in a property of the hydrogel such as swelling degree, impedance, fluorescence, and/or magnetic field, each of which may be transduced into an electrical signal. These electrical signals can then be used to rapidly and continuously monitor the blood concentration of the analytes of interest. In some embodiments, in order to determine the ACT time blood will flow in or adjacent the catheter past a fibrinogen-responsive hydrogel after flowing through a porous bed of clotting activator such as diatomaceous earth. The clotting activator will initiate clotting and the subsequent incorporation of soluble fibrinogen into fibrin-based blood clots. Hence time-dependent clot formation and the ACT can be determined from the measured decrease in fibrinogen concentration. Alternatively, the increase in thrombin concentration can be measured from the signal obtained from the thrombin-responsive hydrogel and correlated to the endogenous thrombin potential. Because binding of the analytes to the hydrogels will be rapid and reversible, it will be possible to measure the value of the ACT and the endogenous thrombin potential continuously in vivo, which are distinct advantages relative to known systems.
  • Catheter Sheath
  • In one embodiment, a catheter-associated sensor system may include a sheath with one or more sensors attached thereto where the sheath can be attached to a catheter, for example by attaching to a side of, or wrapping around, the catheter (FIGS. 3-6). In certain embodiments, the sheath is fabricated using flex circuits (e.g. made of materials such as Parylene, Silicones, Polyurethanes, or Polyimides) so that the sheath can be wrapped around another structure such as a catheter. A sheath designed for catheter mounting may be elongated so that it can be wrapped around the shaft of the catheter.
  • The sheath may wrap around the entire length of the catheter or just at the distal end (FIGS. 3, 5). To facilitate wrapping around the catheter, the sheath may be formed into a curled shape (for example during a curing process, e.g. using heat; see FIGS. 3, 5) or the sheath may be rolled and joined along the edge to retain the rolled shape, and/or the sheath may be attached to the catheter, e.g. using adhesive, to help maintain the curled shape.
  • The sheath may have one or more sensors associated therewith, for example located at the distal end or disposed along its length (FIGS. 3, 5, 6). In some embodiments the sensors may include hydrogel sensors, and in one particular embodiment the sensors may be magnetic hydrogel sensors.
  • In the embodiment shown in FIGS. 3-6, the sheath includes a narrow body with a wide portion at a distal end. One or more sensors are attached to the sheath at the wide portion, which wraps around a distal end of the catheter (FIGS. 3, 5, 6). A plurality of electrical connections run from each sensor along the narrow body of the sheath to the proximal end, where the electrical connections connect with an electronics unit, which collects data from the sensors.
  • The electronics unit may also include a power supply (e.g. one or more batteries) and a telemetry system including an antenna for wireless communications (e.g. for receiving commands and transmitting data) (FIG. 4). Wireless communications may be conducted using any number of suitable protocols such as Bluetooth or ZigBee. The electronics unit may communicate with other computers or smartphones that are local or remote from the sheath using wireless communications or in a wired configuration. Data transfer may be initiated in several ways, including by activation of a touch-sensitive switch on the electronics unit. The electronics unit may be housed in a small package that can be mounted at an end of the catheter, for example distal from the location of the sensors. In some embodiments the narrow body of the sheath may extend through a coupling of the catheter and connect to the electronics unit inside the coupling (FIG. 4).
  • In particular embodiments, the sheath may be made of one or more flexible and/or biocompatible materials (e.g. Parylene, Silicones, PU, PI) and has embedded therein electrical traces and interconnects from the sensor array to a circular processor unit. The processor unit may be dimensioned such as to fit exactly on the top part of the catheter structure, extending the length by less than 5 mm.
  • Various types of sensors can be used with the sheath, although in one particular embodiment the sensors include smart hydrogels with magnetic particles associated therewith in which a magnetometer is used to detect changes in the hydrogel due to interaction with the analyte (see below). In various embodiments the sensors that may be used with the sheath include amperometric (current), potentiometric (voltage), optical (e.g. fluorescence), mechanical (e.g. pressure, volume), magnetic, and inductive (RF frequency shift) sensors. In addition to hydrogels, sensing mechanisms may include various enzymatic and non-enzymatic mechanisms including those employing antibodies and other protein-based sensors.
  • The disclosed catheter sheath sensor system allows intraprocedural, real-time monitoring of changes in electrolytes, blood coagulation status, and injury markers (enzyme etc.) and will save a significant amount of blood draws, additional testing and ensure a higher level of safety by detecting changes in critical blood values as they happen in real-time.
  • Bioreactor
  • When used as part of a bioreactor, an array having one or more sensors is located at the end of a probe to be inserted into the bioreactor (FIG. 7). In some embodiments the probe may have two or more separate portions including a disposable sleeve containing one or more sensors (e.g. hydrogel sensors) and a magnetic detector insert which is inserted into the sleeve. In this configuration, the sleeve interacts with the contents of the bioreactor while the magnetic detector insert is shielded from the contents and therefore can be reused. In this configuration it is particularly advantageous to use magnetic hydrogel sensors such as those disclosed herein, because the magnetic detectors can monitor changes in the magnetic particles associated with the hydrogel sensors without making direct contact. When the magnetic detector insert is inserted into the sleeve, the sensors on the sleeve align with the array of magnetic detectors on the insert, permitting the magnetic sensors to ‘interrogate’ the magnetic hydrogels. The sleeve in various embodiments may include a porous end portion (e.g. a hemispherical mesh cover as shown) which permits passage of analytes so that the analytes can interact with the sensors while protecting the sensors. The electronics for controlling the sensors may be included in the insert portion of the probe adjacent to the magnetic detectors or may be at a remote location.
  • Magnetic Particle-Based Hydrogel Sensors
  • In certain embodiments, the sensor system includes magnetic hydrogel sensors. Magnetic hydrogel sensors use hydrogels, including smart hydrogels, as described above, in which the hydrogel changes shape due to its interaction with an analyte, and detection of the change in the measurable property is detected using magnetic particles, including nanoparticles, associated with the hydrogel.
  • Thus, the volumetric response of stimuli-responsive hydrogels can be monitored by measuring the change in magnetic field intensity (MFI) by the embedded magnetic nanoparticles. Results indicate that it is possible to construct a hydrogel-magnetic particle composite and measure the changes in MFI with the changes in density of magnetic particles and distance from the magnetometer.
  • The disclosed techniques provides a unique combination of magnetic sensors with analyte-responsive hydrogels. Nanoparticles have previously been embedded in hydrogels as part of controlled drug-delivery applications, although the techniques disclosed herein are versatile and can be used in a wide range of applications. As noted above, the specific chemistry of the synthesized hydrogels causes them to respond to a unique stimulus (e.g. interaction with an analyte) by swelling or deswelling 00% their original volume in proportion to the concentration or intensity of the stimulus.
  • In some embodiments, the magnetic particles or nanoparticles may be arranged in a particular alignment in or adjacent to the hydrogel. For example, in one embodiment the sensor system includes a smart hydrogel having magnetic nanoparticles embedded therein, where the magnetic fields of the nanoparticles are vertically aligned. The vertically aligned magnetic nanoparticles embedded in the smart hydrogels will transduce the hydrogel actuation as a change in magnetic field intensity in and around the hydrogel, which is detected by a magnetometer adjacent to the hydrogel (FIGS. 1, 2). This approach provides several advantages relative to other techniques for monitoring hydrogels such as monitoring pressure changes caused by swelling of the hydrogel, chemical sensing techniques (e.g. electrochemical methods), and optical sensing techniques. The hydrogels can be adapted in a number of ways to respond to concentrations of almost any analyte, expanding the potential impact of the proposed technique enormously.
  • One advantage of the disclosed magnetic nanoparticle hydrogel sensor system is its ability to respond to multiple analytes using different hydrogels within the same sensor platform and its adaptability to a wide variety of sensing applications such as in bioreactor composition sensing, point-of-care medical treatment, or as fully-implantable, chronic (continuous) sensors of physiological biomarkers to monitor diseases or treatment states. For example, passive ‘magnetic-hydrogel’ composites may be implanted in a subject's subcutaneous region and active components may be placed on the skin surface for long-term continuous monitoring of biomarkers (FIG. 8). In one embodiment an array of sensors may be implanted under a subject's skin with a wired connection to an electronics unit outside the surface of the subject's skin (FIG. 8, top). In another embodiment, an array of magnetic particle-hydrogel sensors is implanted under the subject's skin and a magnetometer and electronics unit is placed over the hydrogel sensors to detect changes in the magnetic fields induced by analyte-dependent changes in the hydrogels (FIG. 8, bottom). In one particular embodiment a pair of magnetic particle-hydrogel sensors may be implanted near one another, with one being sensitive to an analyte (e.g. glucose) and the other being analyte-insensitive (FIG. 9). Magnetometer readings are then collected from both sensors and a differential signal is determined based on the pairs of readings, canceling out changes in signal due to factors other than changes in analyte level, such as the subject's hydration level and body temperature, among other factors. Sensors may be located in a subject's skin in one or more locations throughout the subject's body including in the arms, legs, torso, or head (including, for example, the earlobe).
  • Preliminary experiments support the many advantages of the disclosed technique. In these experiments processes have been developed to disposed magnetic nanoparticles within a 2 mm thick layer of polydimethylsiloxane (PDMS) and align the particles in strong external magnetic field before the PDMS is completely cured (generally using thermal techniques). Three PDMS composite samples were built for three different concentrations (0.25%, 0.5%, 1% w/w) of magnetic particles (N=3×3) and changes in magnetic-field intensity with distance were measured using a commercial magnetometer for all samples (FIGS. 10, 11). These initial experiments were conducted using a commercially-available coarse triple axis magnetometer (HMC5883L from Honeywell), although other types of magnetic sensing systems may be used. As seen from the results the sensor is overloaded or saturated in the presence of the 0.5% and 1% composites at closer distances (FIG. 12). However it should be noted that (1) there is no hysteresis (a major problem with current techniques) in the measurements, (2) there is a significant (easily resolvable) difference in the field intensity between all the concentrations tested at any particular distance. These initial results convincingly support the listed advantages.
  • Other experiments show the high sensitivity of the magnetic field measurements as a function of distance from the magnetometer (FIG. 13) as well as the sensitivity of the system using a glucose-sensitive magnetic particle hydrogel (FIG. 14) or an osmotic strength-sensitive magnetic particle hydrogel (FIG. 15). FIG. 13 shows the sensitivity of an off-the-shelf magnetometer. Measured changes in the magnetic field are due the movement of a magnetic strip by 5 micrometer increments 2 mm above the magnetometer. The magnetic strip was moved using an automatic (computer controlled) linear actuator 20 times from 0-200 micrometers and the data shows excellent repeatability. This experiment was conducted to demonstrate the ability of magnetically measuring fine physical movements relatively far away (three orders of magnitude) from a low-cost magnetometer. FIG. 14 demonstrates the ability to measure the changes in glucose concentration using a magnetic-hydrogel. In this case the hydrogel is synthesized to be glucose responsive and a prefabricated magnetic film was placed over the hydrogel to form the magnetic hydrogel. The hydrogel was attached to the inside wall a glass-beaker while the magnetometer was aligned to the hydrogel on the outside of the beaker. At a constant pH of 7.3 and in a constant 1× phosphate buffered solution, glucose concentration was changed from 0 mM to 5 mM and the resulting change in the magnetic field was measured using the magnetometer. The solution in the beaker was mildly stirred throughout the experiment. The data artifact seen after the first cycle in FIG. 14 is caused during the act of changing solutions in the beaker. The setup used in experiment that resulted in FIG. 15 is similar to that described above for FIG. 14. Here the hydrogel used was one sensitive to ionic strength. Ionic strength was changed using an automatic flow control system from 1× to 2×PBS in the beaker and the change in magnetic field was measured using the magnetometer. The drift in the data is caused due to the conditioning of the hydrogel.
  • The number and variety of applications of the disclosed magnetic nanoparticle-hydrogel sensor system is enhanced by the ongoing research and development of hydrogel properties and specificities, which will help in the application of this invention in medical device/diagnostic field, among others.
  • In various embodiments, the disclosed sensors may be adapted for use in a variety of fields. In the neurology and psychiatry fields, sensors may be adapted for diagnosing and monitoring symptoms related to addiction, depression, Parkinson's disease, stroke, and blood pressure. In the oral/gastrointestinal field, sensors may be adapted for detection of smoking, monitoring intake of various medications and other drugs, and monitoring changes in acid levels in the esophagus and stomach. In the pulmonology field, sensors may be adapted for monitoring of inhalers as well as diagnosis, monitoring, and management of symptoms related to conditions of the lungs such as asthma and chronic obstructive pulmonary disease (COPD).
  • In the cardiac field, sensors may be adapted for use related to interventional procedures such as monitoring of pH, electrolytes, glucose, troponin, C-reactive protein, troponin, cholesterol components, and guidance and monitoring use of anticoagulants such as monitoring of factors Xa and thrombin. Also in the cardiac field, sensors may be adapted for use with devices such as ICD leads (e.g. for sensing of heart failure and heart attacks), PM leads (e.g. for monitoring of heart failure and heart attacks), and for monitoring clot formation including thrombin generation (thrombin-antithrombin [TAT] complex), endothelial dysfunction (asymmetric dimethylarginine [ADMA]), and platelet-derived inflammation (soluble CD40 ligand [sCD40L]).
  • In the hepatology field, sensors may be adapted for monitoring and/or diagnosing liver enzymes, hepatitis C, fat liver, and liver transplants; in addition, pancreatic activity can be evaluated through monitoring of blood glucose levels in order to assess an individual's or population's diabetes risk level. In the renal field, sensors may be adapted for measuring creatinine levels, monitoring kidney transplants, and monitoring the physiology of dialysis patients. In the hematology field, sensors may be adapted for monitoring iron and hemoglobin levels as well as diagnosing and monitoring treatment of blood cancers (e.g. detecting particular markers). In the urology field, sensors may be adapted for monitoring the prostate including PSA levels. Finally, sensors may be adapted for use before, during, and after surgery to monitor a subject's levels of pH, electrolytes, blood anticoagulation factors, hemoglobin, and lactate levels.
  • Among the advantages of the disclosed magnetic nanoparticle-hydrogel sensor system:
  • (1) No by-products: Unlike electrochemical sensing, the disclosed methods do not produce by-products from the sensing mechanism;
  • (2) Long lifetime: Unlike other common sensing techniques that consume raw materials during sensing, the disclosed hydrogel-based sensing technique does not depend on chemical reactions;
  • (3) Response to multiple analytes: A particular advantage of the proposed approach is its ability to respond to multiple analytes using different hydrogels within the same sensor platform and its adaptability to a wide variety of sensing applications such as in bioreactor composition sensing, point-of-care medical treatment, or as fully implantable, chronic sensors of physiological biomarkers to monitor diseases or treatment states; and
  • (4) Minimum exposure to exogenous materials: In medical device applications, the disclosed sensors are expected to have fewer problems due to a subject's body reacting to foreign objects associated with the sensor because the implanted portion can be as little as the passive hydrogel portion, while the remaining detection components (e.g. the magnetometer and related electronics) can be placed on the surface of the subject's body/skin.
  • Among the many possible applications for the disclosed magnetic nanoparticle-hydrogel sensor system:
  • (1) Bioreactor composition sensing, especially for one-time use reactors;
  • (2) Point-of-care medical treatment;
  • (3) Fully implantable, chronic/continuous sensors of physiological biomarkers to monitor disease states or progress of treatments; and
  • (4) Continuous metabolic sensing in animal research.
  • One possible limitation of the disclosed magnetic nanoparticle-hydrogel sensor system is possible interference when used in high magnetic-field environments, such as in or near MRI systems. The sensing MFI range of the proposed sensor in some embodiments may range from about 300 μT to about 4000 μT. While this range is much higher than the earth's magnetic field range (25-65 μT), it is lower than that seen in magnetic resonance imaging (MRI). Sensor readings may be influenced by strong external magnetic fields, although one way to overcome this limitation may be to have an auxiliary reference magnetometer at a distance from the sensor, for example in a hand-held monitoring device, so that differential magnetic readings can be taken.
  • FIGS. 16 and 17 show alignment of magnetic particles in or adjacent to a hydrogel. FIGS. 16 and 17 each show a hydrogel mounted on a substrate with a layer containing magnetic particles on top of the hydrogel. The hydrogel may be continuously attached to the substrate during use, or the substrate may only be present during formation of the hydrogel and removed from the hydrogel prior to use. In some embodiments, a larger portion of the hydrogel (with or without a separate top layer) may be made and then divided into smaller sections for use. In use, a magnetometer is placed near the hydrogel, for example under the substrate, when present, or near the hydrogel, to detect magnetic fields from the particles associated with the hydrogel.
  • Although the magnetic particles are contained in a layer on top of the hydrogel, in some embodiments the hydrogel itself (or a portion thereof) may contain the particles. The particle-containing layer, when present, may be solid or it may be porous or contain perforations to permit access by the analytes to the hydrogel (FIG. 18). The particle-containing layer may be made of a hydrogel (the same or different from the underlying hydrogel), another polymer, or silicone, among various possible materials.
  • In certain embodiments, a hydrogel and/or top layer may be formed according to the following procedures:
  • (1) Prepare the pre-gel (hydrogel, silicone, epoxy, etc.) and mix magnetic particles to form a homogenous solution;
  • (2) Form a thin layer of solution on a substrate and ensure that the magnetic particles are uniformly dispersed;
  • (3) Subject the film to an external magnetic field with desired field pattern during the polymerization process to ensure that particles in the polymerized layer are aligned;
  • (4) If formed as a separate layer, this layer may then be placed over an analyte-sensitive hydrogel.
  • The depth of the plane along which the particles are aligned may be altered by controlling the magnitude of the externally-applied magnetic fields during the curing process.
  • The magnetic particles in FIG. 16 are arranged in a Halbach array (FIG. 16, inset). The particular arrangement of particles (e.g. with adjacent vertically-aligned and horizontally-aligned particles having their magnetic fields in opposite directions) causes the magnetic field to extend primarily in one direction away from the plane of the hydrogel or particle layer. FIG. 17 shows another arrangement in which the particles are uniformly aligned, for example horizontally, as shown (FIG. 17, inset), or vertically. In the case of a uniform particle arrangement, the magnetic fields extend relatively equally in both directions away from the plane of the hydrogel or particle layer. In various embodiments, the operating distance at which the magnetic fields are detectable range from tens of micrometers to several millimeters from the particles.
  • The Halbach array or uniform magnetic field may be generated in the layer or hydrogel by subjecting the layer or hydrogel to a suitable magnetic field during curing. In particular, the Halbach array particle arrangement may be realized in one of several possible ways: (1) one way to generate this array is to dispense ferromagnetic particles in a polymer homogeneously and form a magnetic composite sheet, as discussed above, and then magnetize the sheet using a magnetizer with a pre-configured pattern. Polymers that can be used, for example but not limited to, are silicones, polyurethanes, polyethylenes, hydrogels, and other polymers; (2) another way is to select a prefabricated, commercially-available Halbach array sheet material and use it to ‘mirror’ its magnetic arrangement into the hydrogel. This may be accomplished by uniformly dispersing permanently magnetized particles on a selected Halbach array, making sure the particles form an array pattern on the sheet. Then the hydrogel pre-gel solution can be dispensed on the sheet containing arranged magnetic particles, followed by polymerization of the pre-gel solution to form a magnetic hydrogel composite. Magnetic particles may be surface modified to polymerize with the pre-gel solution and/or to promote biocompatibility.
  • In various other embodiments, other arrangements of magnetic particles which maximize the magnetic field gradient are also possible, including a setup having an internal and external (to hydrogel) arrangement of magnetic particles/source to (1) shield noise (2) improve the magnetic field gradient.
  • Possible magnetic nanoparticle materials include permanent magnetic particles such as ferro- or ferri-magnetic particles, rare-earth alloys (samarium-cobalt, neodymium-iron-boron), ceramic ferrites (barium or strontium ferrite), and other magnetic materials. The magnetic particle/nanoparticle sizes may range from 20 nm to tens of micrometers, with a typical size being about 1 micrometer. In various embodiments the magnetic particle/nanoparticle concentration range, in either the hydrogel and/or in a separate film layer, is up to 10% by weight. A non-limiting list of analytes that the hydrogel may interact with include glucose, fructose, ionic strength/osmolality, oxidative stress, hydration, pH, CO2, O2, lactate, thrombin and other proteins, and particular cell types. The hydrogel-based sensor systems disclosed herein may be used to determine the presence and levels of the various analytes.
  • Various features and advantages of the invention are set forth in the following claims.

Claims (11)

What is claimed is:
1. A sensor sheath for a catheter, comprising:
a substrate having at least one sensor associated therewith; and
an electronics unit in communication with the at least one sensor,
wherein the substrate is configured to attach to a catheter.
2. The sensor sheath of claim 1, wherein the at least one sensor comprises a hydrogel sensor.
3. The sensor sheath of claim 2, wherein the at least one sensor further comprises a plurality of magnetic particles associated with the hydrogel sensor.
4. The sensor sheath of claim 3, wherein the magnetic particles comprise magnetic nanoparticles.
5. The sensor sheath of claim 3, wherein each of the plurality of magnetic particles has a magnetic field, and wherein the magnetic fields of the plurality of magnetic particles are aligned in the same direction.
6. The sensor sheath of claim 3, wherein each of the plurality of magnetic particles has a magnetic field, and wherein the magnetic fields of the plurality of magnetic particles are aligned in a Halbach array.
7. The sensor sheath of claim 3, wherein the magnetic particles are embedded within the hydrogel sensor.
8. The sensor sheath of claim 3, wherein the hydrogel sensor is sensitive to an analyte.
9. The sensor sheath of claim 3, wherein the magnetic particles are in a layer on top of the hydrogel sensor.
10. The sensor sheath of claim 3, wherein the at least one sensor further comprises a magnetometer adjacent the hydrogel sensor.
11. The sensor sheath of claim 1, wherein the substrate comprises a flexible, biocompatible material, at least a portion of which is curved so as to wrap around a catheter.
US16/449,169 2013-03-11 2019-06-21 Sensor Systems Abandoned US20190313977A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/449,169 US20190313977A1 (en) 2013-03-11 2019-06-21 Sensor Systems

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361851603P 2013-03-11 2013-03-11
US201461927683P 2014-01-15 2014-01-15
PCT/US2014/023352 WO2014164731A1 (en) 2013-03-11 2014-03-11 Sensor systems
US201514774070A 2015-09-09 2015-09-09
US16/449,169 US20190313977A1 (en) 2013-03-11 2019-06-21 Sensor Systems

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US14/774,070 Division US10448895B2 (en) 2013-03-11 2014-03-11 Sensor systems
PCT/US2014/023352 Division WO2014164731A1 (en) 2013-03-11 2014-03-11 Sensor systems

Publications (1)

Publication Number Publication Date
US20190313977A1 true US20190313977A1 (en) 2019-10-17

Family

ID=51658956

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/774,070 Active 2036-02-27 US10448895B2 (en) 2013-03-11 2014-03-11 Sensor systems
US16/449,169 Abandoned US20190313977A1 (en) 2013-03-11 2019-06-21 Sensor Systems

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US14/774,070 Active 2036-02-27 US10448895B2 (en) 2013-03-11 2014-03-11 Sensor systems

Country Status (8)

Country Link
US (2) US10448895B2 (en)
EP (1) EP2967414B1 (en)
JP (1) JP6410789B2 (en)
KR (1) KR102242947B1 (en)
CN (1) CN105246401B (en)
BR (1) BR112015022057B1 (en)
RU (1) RU2670660C9 (en)
WO (1) WO2014164731A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014164731A1 (en) 2013-03-11 2014-10-09 University Of Utah Research Foundation Sensor systems
US9976974B2 (en) 2015-01-27 2018-05-22 University Of Utah Research Foundation Osmolarity-responsive hydrogel sensors and method of use
WO2018020264A1 (en) * 2016-07-28 2018-02-01 Medisieve Ltd. Magnetic mixer and method
KR101768648B1 (en) 2016-07-29 2017-08-17 서울대학교 산학협력단 Ionic touch panel
US20210267573A1 (en) * 2016-09-02 2021-09-02 University Of Utah Research Foundation Implantable and biodegradable smart hydrogel micromechanical resonators with ultrasound readout for biomedical sensing
US11445997B2 (en) 2016-09-02 2022-09-20 University Of Utah Research Foundation Ultrasound imaging of biomarker sensitive hydrogels
US20200093408A1 (en) * 2017-06-12 2020-03-26 Florian Solzbacker Systems, methods, and sensor devices for measuring changes in analyte-sensitive hydrogels
US11931138B2 (en) * 2017-12-14 2024-03-19 Applied Biosensors, LLC Hydrogel sensor assembly
CN109603942B (en) * 2019-02-15 2021-12-24 京东方科技集团股份有限公司 Microfluidic device and microfluidic method
CN109998561B (en) * 2019-05-15 2022-01-28 广西中医药大学附属瑞康医院 Disposable blood coagulation vacuum blood collection tube
CN114630618A (en) 2019-09-09 2022-06-14 马格尼司帝有限公司 Method and apparatus for authenticating three-dimensional objects
CN111543961B (en) * 2020-05-11 2021-03-09 清华大学 Wireless flexible patch type temperature sensor and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6442413B1 (en) * 2000-05-15 2002-08-27 James H. Silver Implantable sensor

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674012A (en) 1970-04-17 1972-07-04 American Optical Corp Blood coagulation detection device
US3841307A (en) 1972-11-15 1974-10-15 P Friedell Subepidermal cannular instrument and method for automated determination of bleeding time and blood loss
US4949722A (en) 1989-09-18 1990-08-21 Roy Bean Method for determining blood platelet adhesiveness
AU654483B2 (en) 1990-04-18 1994-11-10 University Of Utah Research Foundation Crosslinked hydrogels containing azobonds
RU2103915C1 (en) * 1990-07-09 1998-02-10 Естественно-научный институт при Пермском государственном университете им.А.М.Горького Probe for investigating gastric tract
US5447727A (en) 1992-10-14 1995-09-05 The Dow Chemical Company Water-absorbent polymer having improved properties
NO925047L (en) 1992-12-30 1994-07-01 Hafslund Nycomed As Apparatus and use of the apparatus for measuring tendency to clot formation
KR0180315B1 (en) * 1993-06-30 1999-03-20 알렌 제이. 스피겔 Biphasic material
US5427144A (en) 1994-02-24 1995-06-27 Deumed Group Inc. Valve means with fluid retraction means
US6615071B1 (en) 1995-09-20 2003-09-02 Board Of Regents, The University Of Texas System Method and apparatus for detecting vulnerable atherosclerotic plaque
US6753191B2 (en) 1996-11-06 2004-06-22 University Of Pittsburgh Polymerized crystalline colloidal array chemical sensing materials for use in high ionic strength solutions
JPH10151115A (en) * 1996-11-25 1998-06-09 Dainippon Printing Co Ltd Catheter and manufacture therefor
WO1999017095A1 (en) 1997-09-30 1999-04-08 M-Biotech, Inc. Biosensor
US6464699B1 (en) 1997-10-10 2002-10-15 Scimed Life Systems, Inc. Method and apparatus for positioning a diagnostic or therapeutic element on body tissue and mask element for use with same
DE19811017A1 (en) 1998-03-13 1999-09-16 Dade Behring Marburg Gmbh New method for the determination of plasma proteins and factors of hemostasis as well as a new, implantable measuring device
US7179487B1 (en) 1998-06-19 2007-02-20 University Of Utah Research Foundation Hydrogels of water soluble polymers crosslinked by protein domains
US6146327A (en) 1998-08-04 2000-11-14 Wilk; Peter J. Method for in vivo measurement of coagulation rate
CN1275149A (en) 1998-08-13 2000-11-29 株式会社日本触媒 Cross-linked polymer composition swelling in water and process for producing the same
US6475750B1 (en) 1999-05-11 2002-11-05 M-Biotech, Inc. Glucose biosensor
US6514689B2 (en) 1999-05-11 2003-02-04 M-Biotech, Inc. Hydrogel biosensor
US6835553B2 (en) 1999-05-11 2004-12-28 M-Biotech, Inc. Photometric glucose measurement system using glucose-sensitive hydrogel
NL1012223C2 (en) 1999-06-03 2000-12-06 Martil Instr B V Cardiac pacemaker as well as pacemaker unit and electric wire therefor.
EA005743B1 (en) 1999-10-22 2005-06-30 Байосинеджетикс, Инк. Method for providing a chemical compound into a fluid flowing and apparatus therefor
US7625951B2 (en) 2000-07-13 2009-12-01 University Of Kentucky Research Foundation Stimuli-responsive hydrogel microdomes integrated with genetically engineered proteins for high-throughput screening of pharmaceuticals
US7262063B2 (en) * 2001-06-21 2007-08-28 Bio Array Solutions, Ltd. Directed assembly of functional heterostructures
AUPR808001A0 (en) 2001-10-05 2001-10-25 Ragless, Clive Lindsay Method and apparatus for determining concentration of a chemical substance in a solution
WO2003051286A2 (en) 2001-11-01 2003-06-26 Regents Of The University Of Minnesota Hydrogel compositions, devices, and microscale components
JP3943955B2 (en) 2002-02-25 2007-07-11 株式会社タニタ Deep vein thrombosis determination device
US6848384B2 (en) 2002-03-13 2005-02-01 John Andrew Higgins Knuckle
US7150975B2 (en) 2002-08-19 2006-12-19 Animas Technologies, Llc Hydrogel composition for measuring glucose flux
WO2004085712A2 (en) 2003-03-24 2004-10-07 Penn State Research Foundation Multi-functional polymeric materials and their uses
AU2004231988B2 (en) 2003-04-16 2010-04-15 Drexel University Acoustic blood analyzer for assessing blood properties
WO2004096335A1 (en) 2003-04-25 2004-11-11 Cook Incorporated Delivery catheter
US7473548B2 (en) 2003-04-25 2009-01-06 Medtronic, Inc. Optical detector for enzyme activation
US8324184B2 (en) 2003-05-15 2012-12-04 University Of Utah Research Foundation Anti-adhesion composites and methods of use thereof
US20050033136A1 (en) * 2003-08-01 2005-02-10 Assaf Govari Catheter with electrode strip
US7892188B2 (en) 2003-10-22 2011-02-22 Hemosonics, Llc Method and apparatus for characterization of clot formation
US20080044472A1 (en) 2004-01-23 2008-02-21 Garcia Antonio A Photoresponsive Hydrogels
US7884185B2 (en) 2004-07-28 2011-02-08 University Of Delaware Hydrogels and uses thereof
US20060094945A1 (en) 2004-10-28 2006-05-04 Sontra Medical Corporation System and method for analyte sampling and analysis
US20060239986A1 (en) 2005-01-26 2006-10-26 Perez-Luna Victor H Method for the formation of hydrogel multilayers through surface initiated photopolymerization
US8552100B2 (en) 2005-02-23 2013-10-08 The Regents Of The University Of California Flexible hydrogel-based functional composite materials
US20080206894A1 (en) 2005-05-24 2008-08-28 Georgia Tech Research Corporation Bioresponsive Hydrogels
US20080188928A1 (en) 2005-09-16 2008-08-07 Amr Salahieh Medical device delivery sheath
CA2562580C (en) * 2005-10-07 2014-04-29 Inrad, Inc. Drug-eluting tissue marker
US20110095756A1 (en) * 2005-12-21 2011-04-28 Koninklijke Philips Electronics, N.V. Magnetochemical sensor
US9668683B2 (en) * 2005-12-27 2017-06-06 Ascensia Diabetes Care Holdings Ag Electrochemical sensor system using a substrate with at least one aperture and method of making the same
US20120035434A1 (en) 2006-04-12 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Control of a lumen traveling device in a body tube tree
US20120035540A1 (en) 2006-04-12 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Event-based control of a lumen traveling device
US8747870B2 (en) 2006-04-20 2014-06-10 University Of Utah Research Foundation Polymeric compositions and methods of making and using thereof
EP2012803A4 (en) 2006-04-20 2012-08-01 Univ Utah Res Found Polymeric compositions and methods of making and using thereof
US8382987B2 (en) 2006-09-27 2013-02-26 Alessandra Luchini Method for harvesting nanoparticles and sequestering biomarkers
US20100042042A1 (en) * 2006-10-12 2010-02-18 Koninklijke Philips Electronics N.V. Environmental state detection with hydrogel based fully integrated transducer device
EP2079363B1 (en) 2006-10-30 2020-06-10 Elfi-Tech Ltd Method for in vivo measurement of biological parameters
US8265745B2 (en) 2006-12-29 2012-09-11 St. Jude Medical, Atrial Fibillation Division, Inc. Contact sensor and sheath exit sensor
WO2008135916A1 (en) * 2007-05-03 2008-11-13 Koninklijke Philips Electronics N.V. Magnetochemical sensor
US8328720B2 (en) 2007-08-10 2012-12-11 Infotonics Technology Center, Inc. MEMS interstitial prothrombin time test
US20090105799A1 (en) 2007-10-23 2009-04-23 Flowmedica, Inc. Renal assessment systems and methods
CA2710191A1 (en) * 2007-12-21 2009-07-09 T2 Biosystems, Inc. Magnetic resonance system with implantable components and methods of use thereof
US20090170209A1 (en) 2007-12-29 2009-07-02 Music Germlin, Inc Hydrogel chemical sensor
US8283384B2 (en) 2008-01-24 2012-10-09 University Of Utah Research Foundation Adhesive complex coacervates and methods of making and using thereof
EP2247645B1 (en) 2008-02-13 2017-12-06 Hyperbranch Medical Technology, Inc. Crosslinked polyalkyleneimine hydrogels with tunable degradation rates
JP5147452B2 (en) * 2008-02-26 2013-02-20 キヤノン株式会社 Target substance detection method and kit using magnetic biosensor
US20090240121A1 (en) 2008-03-21 2009-09-24 Nova Biomedical Corporation Intravascular sensor and insertion set combination
JP2009276089A (en) * 2008-05-12 2009-11-26 Canon Inc Stirring method of liquid composition, detection method and detection kit
EP2283362A1 (en) * 2008-05-20 2011-02-16 Cantimer Incorporated Methods, systems and devices for analyzing a biological fluid sample following ion exchange
WO2010002479A1 (en) 2008-07-03 2010-01-07 Lowery Thomas Jay Jr Magnetic nanosensor compositions and bioanalytical assays therefor
US20110280914A1 (en) 2009-01-30 2011-11-17 University Of Utah Research Foundation Hydrogels crosslinked with gold nanoparticles and methods of making and using thereof
US8317737B2 (en) 2009-02-25 2012-11-27 The Invention Science Fund I, Llc Device for actively removing a target component from blood or lymph of a vertebrate subject
US8708907B2 (en) 2009-05-06 2014-04-29 Elfi-Tech Method and apparatus for determining one or more blood parameters from analog electrical signals
US8283398B2 (en) * 2009-07-29 2012-10-09 Xerox Corporation Polyhedral silsesquioxane modified polyimide containing intermediate transfer members
US20110053173A1 (en) 2009-08-28 2011-03-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Game with detection capability
US8810417B2 (en) 2009-08-28 2014-08-19 The Invention Science Fund I, Llc Beverage immersate with detection capability
KR101791827B1 (en) * 2009-10-02 2017-10-30 메드트로닉 좀드 인코퍼레이티드 Endotracheal tube apparatus
WO2011066718A1 (en) 2009-12-01 2011-06-09 The Hong Kong University Of Science And Technology Compositions containing thermally-induced self-assembly of nonionic surfactants and their application in smart glass technologies
WO2011088213A1 (en) 2010-01-15 2011-07-21 University Of Utah Research Foundation Crosslinked hydrogels and methods of making and using thereof
US9500186B2 (en) 2010-02-01 2016-11-22 Medipacs, Inc. High surface area polymer actuator with gas mitigating components
US20130143821A1 (en) 2010-02-04 2013-06-06 University Of Tennessee Research Foundation Hydrophobically-modified hyaluronan and methods of making and using thereof
US8999916B2 (en) 2010-03-31 2015-04-07 Agency For Science, Technology And Research Crosslinked peptide hydrogels
EP2433562B1 (en) 2010-09-28 2014-07-09 BIOTRONIK SE & Co. KG Medical sensor system for detecting at least one feature in at least one animal and/or human body
US8663563B2 (en) 2010-12-03 2014-03-04 Purdue Research Foundation Reflective diffractometric hydrogel sensor for biological and chemical detection
US9375179B2 (en) * 2010-12-23 2016-06-28 Biosense Webster, Inc. Single radio-transparent connector for multi-functional reference patch
US8792962B2 (en) 2010-12-30 2014-07-29 Biosense Webster, Inc. Catheter with single axial sensors
EP2667778B1 (en) 2011-01-28 2021-04-28 Bar Ilan University Method and system for non-invasively monitoring biological or biochemical parameters of individual
WO2012170401A2 (en) 2011-06-06 2012-12-13 Percuvision, Llc Sensing catheter emitting radiant energy
US9737244B2 (en) * 2012-03-13 2017-08-22 Purdue Research Foundation Sensor having ferrogel with magnetic particles
WO2014164731A1 (en) 2013-03-11 2014-10-09 University Of Utah Research Foundation Sensor systems

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6442413B1 (en) * 2000-05-15 2002-08-27 James H. Silver Implantable sensor

Also Published As

Publication number Publication date
JP6410789B2 (en) 2018-10-24
EP2967414A1 (en) 2016-01-20
RU2670660C2 (en) 2018-10-24
US10448895B2 (en) 2019-10-22
CN105246401B (en) 2019-11-22
WO2014164731A1 (en) 2014-10-09
KR20150143432A (en) 2015-12-23
KR102242947B1 (en) 2021-04-22
BR112015022057A2 (en) 2017-07-18
EP2967414B1 (en) 2019-12-18
CN105246401A (en) 2016-01-13
RU2015138942A (en) 2017-04-17
BR112015022057B1 (en) 2022-06-28
JP2016517306A (en) 2016-06-16
RU2670660C9 (en) 2018-12-12
US20160015323A1 (en) 2016-01-21
EP2967414A4 (en) 2017-02-22

Similar Documents

Publication Publication Date Title
US20190313977A1 (en) Sensor Systems
Yetisen et al. Glucose‐sensitive hydrogel optical fibers functionalized with phenylboronic acid
JP6744019B2 (en) Devices and associated methods for skin fluid characterization of biofluids
AU2007317787B2 (en) NMR systems for in vivo detection of analytes
US9737244B2 (en) Sensor having ferrogel with magnetic particles
EP2349442B1 (en) Method and device for detection of bioavailable drug concentration in a fluid sample
US20100173421A1 (en) Sensor
JP2011503541A (en) Small magnet and RF coil for magnetic resonance relaxation measurements
US20150087945A1 (en) Laser-scribed ferrogel sensor with magnetic particles
Gil et al. Smart implanted access port catheter for therapy intervention with pH and lactate biosensors
US20200093408A1 (en) Systems, methods, and sensor devices for measuring changes in analyte-sensitive hydrogels
dos Santos et al. Biosensors
Saylan et al. Nanosensors for medical diagnosis
Yamada et al. Detection and estimation of low-concentration magnetic fluid inside body by a needle-type GMR sensor
Wan et al. Millimeter-scale magnetic implants paired with a fully integrated wearable device for wireless biophysical and biochemical sensing
Park Wireless chemical sensing schemes using environmentally sensitive hydrogels
Naegele et al. Integration of a silicon sensor for application in biomedical analytics
Corrie et al. Analyst RSC
Córcoles et al. Requirements for an Invasive Sensor

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: UNIVERSITY OF UTAH RESEARCH FOUNDATION, UTAH

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UNIVERSITY OF UTAH;REEL/FRAME:055890/0386

Effective date: 20140414

Owner name: UNIVERSITY OF UTAH, UTAH

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TATHIREDDY, PRASHANT;SOLZBACHER, FLORIAN;MARROUCHE, NASSIR;AND OTHERS;SIGNING DATES FROM 20140307 TO 20140317;REEL/FRAME:055890/0363

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION